Which NSAID is currently being studied for Alzheimer's disease?

The nonsteroidal anti-inflammatory drug (NSAID) that is being studied for its potential impact on Alzheimer's disease is sulindac. Research has indicated that certain NSAIDs may have neuroprotective benefits and could potentially modulate the inflammatory processes involved in neurodegenerative diseases, including Alzheimer's.

Sulindac, in particular, has shown promise due to its ability to influence pathways relevant to the pathology of Alzheimer’s, such as reducing the formation of amyloid plaques and protecting neuronal function. This interest in sulindac stems from the idea that inflammation plays a role in the progression of Alzheimer's disease and managing that inflammation could lead to positive outcomes in the disease progression.

Other NSAIDs listed may have been studied in relation to various aspects of pain management or other conditions, but current research into Alzheimer's disease has focused more on sulindac's specific mechanisms and potential benefits in this context.